NCT00430729 - Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112) | Biotech Hunter

Enrollment

1,100

Participants

Timeline

Start Date

January 31, 2003

Conditions

Chronic Obstructive Pulmonary DiseaseCOPD

Interventions

DRUG

Roflumilast

Trial Locations (14)

ALTANA Pharma, Cities in Australia

ALTANA Pharma, Cities in Austria

ALTANA Pharma, Cities in Canada

ALTANA Pharma, Cities in France

ALTANA Pharma, Cities in Hungary

ALTANA Pharma, Cities in Italy

ALTANA Pharma, Cities in the Netherlands

ALTANA Pharma, Cities in Poland

ALTANA Pharma, Cities in Portugal

ALTANA Pharma, Cities in the Russian Federation

ALTANA Pharma, Cities in South Africa

ALTANA Pharma, Cities in Spain

ALTANA Pharma, Cities in Switzerland

ALTANA Pharma, Cities in the United Kingdom